Loading…

Clinical characteristics of patients with late-onset multiple sclerosis

We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertai...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neurology 2008-05, Vol.255 (5), p.697-702
Main Authors: Kis, B., Rumberg, B., Berlit, P.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03
cites cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03
container_end_page 702
container_issue 5
container_start_page 697
container_title Journal of neurology
container_volume 255
creator Kis, B.
Rumberg, B.
Berlit, P.
description We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p < 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.
doi_str_mv 10.1007/s00415-008-0778-x
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_20780266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20780266</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</originalsourceid><addsrcrecordid>eNp1kE2LFDEQhoMo7uzqD_AijaC3aOWjO52jDLorLHjRc0hnKm6WTPeYSuP6780wgwuCpzrUU1VvPYy9EvBeAJgPBKBFzwFGDsaM_OEJ2witJBe6t0_ZBpQG3qteX7BLontoYGs8ZxdilKNSVm_Y9TanOQWfu3Dniw8VS6KaAnVL7A6-Jpwrdb9Sveuyr8iXmbB2-zXXdMjYUchYFkr0gj2LPhO-PNcr9v3zp2_bG3779frL9uMtD1pB5bpHaycQaMxu8rvByN1ke2Em0eJE22th7dDSAQ5D9MrHaJS3quEGBURQV-zdae-hLD9XpOr2iQLm7GdcVnISzAhyGBr45h_wflnL3LI5KUahtBllg8QJCu0JKhjdoaS9L7-dAHdU7E6KXTPnjordQ5t5fV68TnvcPU6cnTbg7Rnw1MTG4ueQ6C8nQStr4fiKPHHUWvMPLI8J_3_9D85dk2Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218134782</pqid></control><display><type>article</type><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><source>Springer Nature</source><creator>Kis, B. ; Rumberg, B. ; Berlit, P.</creator><creatorcontrib>Kis, B. ; Rumberg, B. ; Berlit, P.</creatorcontrib><description>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p &lt; 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-008-0778-x</identifier><identifier>PMID: 18283394</identifier><identifier>CODEN: JNRYA9</identifier><language>eng</language><publisher>Darmstadt: Steinkopff-Verlag</publisher><subject>Adolescent ; Adult ; Age Factors ; Age of Onset ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Brain - pathology ; Brain - physiopathology ; Central Nervous System - pathology ; Central Nervous System - physiopathology ; Cohort Studies ; Diagnostic Errors ; Disease Progression ; Drug Resistance ; Evoked Potentials ; Female ; Humans ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Movement Disorders - diagnosis ; Movement Disorders - epidemiology ; Movement Disorders - physiopathology ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis - physiopathology ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Multiple Sclerosis, Chronic Progressive - diagnosis ; Multiple Sclerosis, Chronic Progressive - epidemiology ; Multiple Sclerosis, Chronic Progressive - physiopathology ; Multiple Sclerosis, Relapsing-Remitting - diagnosis ; Multiple Sclerosis, Relapsing-Remitting - epidemiology ; Multiple Sclerosis, Relapsing-Remitting - physiopathology ; Neurology ; Neuroradiology ; Neurosciences ; Oligoclonal Bands - cerebrospinal fluid ; Original Communication ; Retrospective Studies ; Severity of Illness Index ; Spinal Cord - pathology ; Spinal Cord - physiopathology ; Steroids - therapeutic use</subject><ispartof>Journal of neurology, 2008-05, Vol.255 (5), p.697-702</ispartof><rights>Steinkopff-Verlag 2008</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</citedby><cites>FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=20439900$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18283394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kis, B.</creatorcontrib><creatorcontrib>Rumberg, B.</creatorcontrib><creatorcontrib>Berlit, P.</creatorcontrib><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p &lt; 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Age of Onset</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Brain - pathology</subject><subject>Brain - physiopathology</subject><subject>Central Nervous System - pathology</subject><subject>Central Nervous System - physiopathology</subject><subject>Cohort Studies</subject><subject>Diagnostic Errors</subject><subject>Disease Progression</subject><subject>Drug Resistance</subject><subject>Evoked Potentials</subject><subject>Female</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Movement Disorders - diagnosis</subject><subject>Movement Disorders - epidemiology</subject><subject>Movement Disorders - physiopathology</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis - physiopathology</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Multiple Sclerosis, Chronic Progressive - diagnosis</subject><subject>Multiple Sclerosis, Chronic Progressive - epidemiology</subject><subject>Multiple Sclerosis, Chronic Progressive - physiopathology</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - epidemiology</subject><subject>Multiple Sclerosis, Relapsing-Remitting - physiopathology</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Oligoclonal Bands - cerebrospinal fluid</subject><subject>Original Communication</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>Spinal Cord - pathology</subject><subject>Spinal Cord - physiopathology</subject><subject>Steroids - therapeutic use</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kE2LFDEQhoMo7uzqD_AijaC3aOWjO52jDLorLHjRc0hnKm6WTPeYSuP6780wgwuCpzrUU1VvPYy9EvBeAJgPBKBFzwFGDsaM_OEJ2witJBe6t0_ZBpQG3qteX7BLontoYGs8ZxdilKNSVm_Y9TanOQWfu3Dniw8VS6KaAnVL7A6-Jpwrdb9Sveuyr8iXmbB2-zXXdMjYUchYFkr0gj2LPhO-PNcr9v3zp2_bG3779frL9uMtD1pB5bpHaycQaMxu8rvByN1ke2Em0eJE22th7dDSAQ5D9MrHaJS3quEGBURQV-zdae-hLD9XpOr2iQLm7GdcVnISzAhyGBr45h_wflnL3LI5KUahtBllg8QJCu0JKhjdoaS9L7-dAHdU7E6KXTPnjordQ5t5fV68TnvcPU6cnTbg7Rnw1MTG4ueQ6C8nQStr4fiKPHHUWvMPLI8J_3_9D85dk2Y</recordid><startdate>20080501</startdate><enddate>20080501</enddate><creator>Kis, B.</creator><creator>Rumberg, B.</creator><creator>Berlit, P.</creator><general>Steinkopff-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20080501</creationdate><title>Clinical characteristics of patients with late-onset multiple sclerosis</title><author>Kis, B. ; Rumberg, B. ; Berlit, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Age of Onset</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Brain - pathology</topic><topic>Brain - physiopathology</topic><topic>Central Nervous System - pathology</topic><topic>Central Nervous System - physiopathology</topic><topic>Cohort Studies</topic><topic>Diagnostic Errors</topic><topic>Disease Progression</topic><topic>Drug Resistance</topic><topic>Evoked Potentials</topic><topic>Female</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Movement Disorders - diagnosis</topic><topic>Movement Disorders - epidemiology</topic><topic>Movement Disorders - physiopathology</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis - physiopathology</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Multiple Sclerosis, Chronic Progressive - diagnosis</topic><topic>Multiple Sclerosis, Chronic Progressive - epidemiology</topic><topic>Multiple Sclerosis, Chronic Progressive - physiopathology</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - epidemiology</topic><topic>Multiple Sclerosis, Relapsing-Remitting - physiopathology</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Oligoclonal Bands - cerebrospinal fluid</topic><topic>Original Communication</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>Spinal Cord - pathology</topic><topic>Spinal Cord - physiopathology</topic><topic>Steroids - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kis, B.</creatorcontrib><creatorcontrib>Rumberg, B.</creatorcontrib><creatorcontrib>Berlit, P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Proquest Health &amp; Medical Complete</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kis, B.</au><au>Rumberg, B.</au><au>Berlit, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics of patients with late-onset multiple sclerosis</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2008-05-01</date><risdate>2008</risdate><volume>255</volume><issue>5</issue><spage>697</spage><epage>702</epage><pages>697-702</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><coden>JNRYA9</coden><abstract>We evaluated clinical presentation, cerebrospinal fluid (CSF), and magnetic resonance imaging (MRI) in patients with late-onset multiple sclerosis (LOMS). Fifty-two patients with definitive multiple sclerosis (MS) diagnosed after the age of 50 years were identified between 1991 and 2002. Data pertaining to clinical characteristics, CSF analysis, and cerebral and spinal MRI were compared with those of 52 young-onset MS (YOMS) patients matched for sex and disease duration. Mean age at the time of diagnosis was 57 years in the LOMS group – the oldest patient was 82 – and 29 years in the YOMS group. Motor symptoms were significantly more often present in the LOMS than in patients with YOMS (90 % vs. 67 %, p = 0.014). Visual symptoms, residual signs of optic neuritis, and dysarthria were less frequent for LOMS. Sensory symptoms, ataxia, oculomotor symptoms, cognitive disorder, or fatigue did not differ between both groups. The majority of LOMS patients (83 %) had a primary progressive disease course, whereas 94 % of the YOMS group had a relapsing-remitting course. MRI showed typical multifocal supratentorial (LOMS vs. YOMS: 96 % vs. 98 %) and infratentorial (44 % vs. 62 %) lesions without significant group differences. Of particular interest, spinal lesions were more common (81 %) in LOMS compared to YOMS (48 %, p = 0.024), and cerebellar lesions were less frequent in the LOMS group (11 % vs. 44 %, p = 0.001). Gadolinium-enhanced lesions were initially present in less LOMS patients (15 %) than in YOMS (63 %, p &lt; 0.001). CSF analysis revealed pleocytosis less frequently in LOMS (34 %) compared to YOMS (67 %, p = 0.006) but oligoclonal banding occurred without in both groups without differences. YOMS patients responded to corticosteroids (93 %) to a significantly greater degree than LOMS patients (73 %; p = 0.004). For individuals who develop LOMS, a primary progressive course is frequent, with motor symptoms as the prominent feature. Vigilance is necessary to recognise MS in this population because of its unusual presentation.</abstract><cop>Darmstadt</cop><pub>Steinkopff-Verlag</pub><pmid>18283394</pmid><doi>10.1007/s00415-008-0778-x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-5354
ispartof Journal of neurology, 2008-05, Vol.255 (5), p.697-702
issn 0340-5354
1432-1459
language eng
recordid cdi_proquest_miscellaneous_20780266
source Springer Nature
subjects Adolescent
Adult
Age Factors
Age of Onset
Aged
Aged, 80 and over
Biological and medical sciences
Brain - pathology
Brain - physiopathology
Central Nervous System - pathology
Central Nervous System - physiopathology
Cohort Studies
Diagnostic Errors
Disease Progression
Drug Resistance
Evoked Potentials
Female
Humans
Magnetic Resonance Imaging
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Movement Disorders - diagnosis
Movement Disorders - epidemiology
Movement Disorders - physiopathology
Multiple Sclerosis - diagnosis
Multiple Sclerosis - epidemiology
Multiple Sclerosis - physiopathology
Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis
Multiple Sclerosis, Chronic Progressive - diagnosis
Multiple Sclerosis, Chronic Progressive - epidemiology
Multiple Sclerosis, Chronic Progressive - physiopathology
Multiple Sclerosis, Relapsing-Remitting - diagnosis
Multiple Sclerosis, Relapsing-Remitting - epidemiology
Multiple Sclerosis, Relapsing-Remitting - physiopathology
Neurology
Neuroradiology
Neurosciences
Oligoclonal Bands - cerebrospinal fluid
Original Communication
Retrospective Studies
Severity of Illness Index
Spinal Cord - pathology
Spinal Cord - physiopathology
Steroids - therapeutic use
title Clinical characteristics of patients with late-onset multiple sclerosis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T21%3A44%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20of%20patients%20with%20late-onset%20multiple%20sclerosis&rft.jtitle=Journal%20of%20neurology&rft.au=Kis,%20B.&rft.date=2008-05-01&rft.volume=255&rft.issue=5&rft.spage=697&rft.epage=702&rft.pages=697-702&rft.issn=0340-5354&rft.eissn=1432-1459&rft.coden=JNRYA9&rft_id=info:doi/10.1007/s00415-008-0778-x&rft_dat=%3Cproquest_cross%3E20780266%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c430t-45e99b01e77dbad672db9517b1339f95419961820e66fa3aff73a93e777e10f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=218134782&rft_id=info:pmid/18283394&rfr_iscdi=true